Psilocybin Mushroom Products in Australia: Legal Status and Medical Access
Psilocybin mushroom products have become a topic of significant interest in Australia. However, a simple and crucial fact exists: there are currently no TGA-approved psilocybin products available for general sale . Any product containing psilocybin is an unapproved therapeutic good that has not been evaluated for safety, quality, or efficacy . Consequently, this guide explores the legal reality, the strict medical pathway for access, and the new quality standards that apply to legal psilocybin products in Australia.
The Legal Status of Psilocybin Products
The legal framework for psilocybin is clear and strict. Since July 1, 2023, the Therapeutic Goods Administration (TGA) has permitted the prescribing of psilocybin for treatment-resistant depression (TRD) . For this specific medical use, psilocybin is classified as a Schedule 8 (Controlled Drug) medicine . Nevertheless, for all other purposes, including recreational use, psilocybin remains a Schedule 9 (Prohibited Substance) .
Crucially, there are currently no psilocybin products registered on the Australian Register of Therapeutic Goods (ARTG) . The TGA has not evaluated any product for quality, safety, or efficacy . Consequently, any psilocybin product sold online or in stores is unregulated and illegal.
The Only Legal Access: The Medical Pathway
Access to psilocybin products is restricted to a very specific, controlled medical pathway . The only legal ways to access psilocybin are through the TGA’s Authorised Prescriber (AP) scheme or participation in an approved clinical trial .
Who Can Prescribe?
Only specialist psychiatrists registered with the Australian Health Practitioner Regulation Agency (AHPRA) and who are Fellows of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) can prescribe psilocybin . To become an Authorised Prescriber, the psychiatrist must obtain approval from a Human Research Ethics Committee (HREC) and then receive authorisation from the TGA .
Who Can Receive Treatment?
The treatment is reserved for patients with treatment-resistant depression who have not responded to other therapies . Psychiatrists must consider all other TGA-approved treatment options before prescribing psilocybin .
How Is Treatment Delivered?
Psilocybin is not a take-home medication. The TGA explicitly states that “protocols that allow patients to take these medicines home are not accepted under the AP scheme” . Treatment must occur in an appropriately supervised healthcare setting with good clinical governance practices . The approved psychiatrist must remain present throughout the treatment session . Patients cannot access the medicine outside this health setting .
Legal Psilocybin Products: Quality Standards (TGO 113)
For the psilocybin products used in the medical pathway, the TGA has established specific quality standards. The Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024 sets minimum quality requirements for psilocybin medicines used in Australia .
What the Standard Covers:
The standard applies to both plant-derived and synthetic psilocybin . It covers:
- Plant-derived psilocybin (extract or isolate from the Psilocybe cubensis mushroom)
- Synthetic psilocybin (produced using precursor ingredients rather than from mushrooms)
- Finished products (must be in the form of a capsule for oral administration)
Key Requirements:
- Identification: The psilocybin mushroom material used must undergo macroscopic examination, microscopic examination, and chromatographic procedures .
- Assay Limits: The products must meet specified concentration ranges for psilocybin, psilocin, and other compounds .
- Labelling: Products must include specific information on the label in English .
- Testing: Products must comply with specified tests for purity and contaminants .
Manufacturing and Supply
Only licensed manufacturers can produce psilocybin products for the medical pathway . One Australian company, Breathe Life Sciences, holds a licence to manufacture both MDMA and psilocybin . The facility tests products at multiple stages—before purchase, upon arrival, and after the finished product is made—for impurities including heavy metals, pesticides, bacteria, and chemical consistency . As of 2026, Breathe Life Sciences manufactures more than 3 million products annually for over 300 clients .
Current Access Numbers
Access to psilocybin therapy remains limited. The TGA reports that 40 psychiatrists hold approvals for both MDMA and psilocybin outside of clinical trials . Across Australia, approximately 74 patients have received psilocybin therapy outside of clinical trials .
Conclusion
Psilocybin mushroom products are illegal for general sale and possession in Australia. The only legal access is through a strict medical pathway for treatment-resistant depression, using unapproved products that must meet the quality standards of TGO 113. Products sold online or in stores are unregulated, potentially dangerous, and illegal. For Australians, the safest and only legal option is through a registered psychiatrist within the TGA’s Authorised Prescriber scheme. This guide is for educational purposes only and does not constitute legal advice.